Literature DB >> 7588985

Surfactant replacement therapy for non-respiratory distress syndrome neonatal respiratory disease--research or clinical application?

A Greenough1.   

Abstract

Research studies have highlighted both physiological and pathological evidence to incriminate surfactant abnormality and/or deficiency in many neonatal respiratory diseases. Data from animal models and clinical studies support the concept that surfactant replacement therapy (SRT) may have a role to play in such problems. There is now, therefore, a need to perform further randomized controlled trials to assess the appropriate clinical application of SRT in non-respiratory distress syndrome neonatal respiratory disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588985      PMCID: PMC7101983          DOI: 10.1007/BF02155101

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  Phospholipid and surfactant protein A concentrations in tracheal aspirates from infants requiring extracorporeal membrane oxygenation.

Authors:  K C Bui; F J Walther; R David-Cu; M Garg; D Warburton
Journal:  J Pediatr       Date:  1992-08       Impact factor: 4.406

2.  Pathophysiology of congenital diaphragmatic hernia. III: Exogenous surfactant therapy for the high-risk neonate with CDH.

Authors:  P L Glick; C L Leach; G E Besner; E A Egan; F C Morin; A Malanowska-Kantoch; L K Robinson; A Brody; A S Lele; M McDonnell
Journal:  J Pediatr Surg       Date:  1992-07       Impact factor: 2.545

Review 3.  Surfactant inactivation and surfactant replacement in experimental models of ARDS.

Authors:  B Robertson
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1991

4.  [Effect of a bovine surfactant in very low birth weight premature infants with congenital pneumonia].

Authors:  L Gortner; F Pohlandt; P Bartmann
Journal:  Monatsschr Kinderheilkd       Date:  1990-05       Impact factor: 0.323

5.  Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material.

Authors:  F M LaForce; W J Kelly; G L Huber
Journal:  Am Rev Respir Dis       Date:  1973-10

6.  Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency.

Authors:  A Lotze; G R Knight; K D Anderson; W M Hull; J A Whitsett; R M O'Donnell; G Martin; D I Bulas; B L Short
Journal:  J Pediatr Surg       Date:  1994-03       Impact factor: 2.545

7.  Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf).

Authors:  C P Speer; B Götze; T Curstedt; B Robertson
Journal:  Pediatr Res       Date:  1991-07       Impact factor: 3.756

8.  Surfactant treatment of full-term newborns with respiratory failure.

Authors:  R L Auten; R H Notter; J W Kendig; J M Davis; D L Shapiro
Journal:  Pediatrics       Date:  1991-01       Impact factor: 7.124

9.  Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation.

Authors:  A Lotze; G R Knight; G R Martin; D I Bulas; W M Hull; R M O'Donnell; J A Whitsett; B L Short
Journal:  J Pediatr       Date:  1993-02       Impact factor: 4.406

10.  Surfactant therapy in full-term neonates with severe respiratory failure.

Authors:  H Khammash; M Perlman; J Wojtulewicz; M Dunn
Journal:  Pediatrics       Date:  1993-07       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.